IL146148A0 - Use of phthalazine derivatives - Google Patents

Use of phthalazine derivatives

Info

Publication number: IL146148A0
Authority: IL; Israel
Prior art keywords: phthalazine derivatives; parp; inhibitors; homologous enzymes; phthalazine
Prior art date: 1999-05-11

Application number

IL14614800A

Other languages

English (en)

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-11

Filing date

2000-05-03

Publication date

2002-07-25

2000-05-03 Application filed by Basf Ag filed Critical Basf Ag

2002-07-25 Publication of IL146148A0 publication Critical patent/IL146148A0/xx

Links

LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title abstract 3
108090000790 Enzymes Proteins 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 2
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL14614800A 1999-05-11 2000-05-03 Use of phthalazine derivatives IL146148A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19921567A DE19921567A1 (de)	1999-05-11	1999-05-11	Verwendung von Phthalazine-Derivaten
PCT/EP2000/003967 WO2000067734A2 (fr)	1999-05-11	2000-05-03	Utilisation de derives de phtalazine

Publications (1)

Publication Number	Publication Date
IL146148A0 true IL146148A0 (en)	2002-07-25

Family

ID=7907632

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14614800A IL146148A0 (en)	1999-05-11	2000-05-03	Use of phthalazine derivatives

Country Status (20)

Country	Link
US (1)	US6903098B1 (fr)
EP (1)	EP1231982B1 (fr)
JP (1)	JP2003502286A (fr)
KR (1)	KR20020000642A (fr)
CN (1)	CN1399573A (fr)
AT (1)	ATE357272T1 (fr)
AU (1)	AU5064000A (fr)
BG (1)	BG106056A (fr)
BR (1)	BR0010428A (fr)
CA (1)	CA2372704A1 (fr)
CZ (1)	CZ20014038A3 (fr)
DE (2)	DE19921567A1 (fr)
ES (1)	ES2284499T3 (fr)
HU (1)	HUP0202477A3 (fr)
IL (1)	IL146148A0 (fr)
NO (1)	NO20015462D0 (fr)
PL (1)	PL352150A1 (fr)
SK (1)	SK286676B6 (fr)
TR (1)	TR200103236T2 (fr)
WO (1)	WO2000067734A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6291425B1 (en)	1999-09-01	2001-09-18	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
EP1223932A4 (fr) *	1999-10-01	2003-01-15	Smithkline Beecham Corp	Composes et methodes
NZ521792A (en) *	2000-03-20	2004-06-25	N Gene Res Lab Inc	Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and use in treating conditions connected with oxygen deficiency
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
KR100955015B1 (ko) *	2001-08-15	2010-04-28	이코스 코포레이션	2ｈ-프탈라진-1-온 및 이것의 사용 방법
DE60335359D1 (de)	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
ATE405658T1 (de)	2002-07-26	2008-09-15	Basf Plant Science Gmbh	Neue selektionsverfahren
JP4520406B2 (ja)	2002-10-01	2010-08-04	田辺三菱製薬株式会社	イソキノリン化合物及びその医薬用途
US7501412B2 (en)	2002-11-22	2009-03-10	Mitsubishi Tanabe Pharma Corporation	Isoquinoline compounds and medicinal use thereof
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
CN101137752B (zh)	2005-03-08	2013-04-03	巴斯福植物科学有限公司	增强表达的内含子序列
CA2615374A1 (fr) *	2005-07-18	2007-01-25	Ernest Kun Kun	Traitement du cancer
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
WO2008147418A1 (fr) *	2006-06-12	2008-12-04	Bipar Sciences, Inc.	Procédé permettant de traiter des maladies avec des inhibiteurs de parp
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
JP2010502730A (ja) *	2006-09-05	2010-01-28	バイパーサイエンシズ，インコーポレイティド	癌の治療法
CA2662337A1 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Inhibition de la synthese d'acides gras au moyen d'inhibiteurs parp et methodes de traitement associees
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
DK2120579T3 (da) *	2006-12-28	2014-02-03	Abbvie Inc	Inhibitorer af poly(ADP-ripose)polymerase
US8466150B2 (en) *	2006-12-28	2013-06-18	Abbott Laboratories	Inhibitors of poly(ADP-ribose)polymerase
US20090023727A1 (en) *	2007-07-05	2009-01-22	Muhammad Hashim Javaid	Phthalazinone derivatives
MX2010002749A (es)	2007-09-14	2010-06-25	Astrazeneca Ab	Derivados de ftalazinona.
KR20100102607A (ko) *	2007-11-12	2010-09-24	바이파 사이언스 인코포레이티드	Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CN103169973A (zh) *	2007-11-12	2013-06-26	彼帕科学公司	使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CA2708157A1 (fr) *	2007-12-07	2009-06-11	Bipar Sciences, Inc.	Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
AR070221A1 (es)	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CA2713156A1 (fr) *	2008-02-04	2009-08-13	Bipar Sciences, Inc.	Procedes de diagnostic et de traitement de maladies mediees par parp
ES2625817T3 (es)	2008-08-06	2017-07-20	Medivation Technologies, Inc.	Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
ES2598178T5 (es)	2008-10-07	2023-12-26	Kudos Pharm Ltd	Formulación farmacéutica 514
US10316304B2 (en)	2009-11-27	2019-06-11	Basf Plant Science Company Gmbh	Chimeric endonucleases and uses thereof
WO2011064751A1 (fr)	2009-11-27	2011-06-03	Basf Plant Science Company Gmbh	Endonucléases chimériques et utilisations de celles-ci
EP2504439B1 (fr)	2009-11-27	2016-03-02	BASF Plant Science Company GmbH	Endonucléases optimisées et leurs utilisations
CA2787844C (fr)	2010-02-03	2019-08-27	Biomarin Pharmaceutical Inc.	Inhibiteurs a base de dihydropyridophtalazinone de la poly(adp-ribose) polymerase (parp) utilisables dans le cadre du traitement de maladies associees a un deficit en pten
PT2533640T (pt) *	2010-02-08	2017-01-03	Medivation Technologies Inc	Processos de síntese de derivados de di-hidropiridoftalazinona
JP2013526514A (ja)	2010-05-10	2013-06-24	ラディカル・セラピューティックス・インコーポレイテッド	リポ酸およびニトロキシド誘導体およびその使用
NZ609490A (en)	2010-10-21	2015-06-26	Biomarin Pharm Inc	Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012074840A2 (fr)	2010-11-22	2012-06-07	The General Hospital Corporation	Compositions et procédés d'imagerie in vivo
CN103130723B (zh)	2011-11-30	2015-01-14	成都地奥制药集团有限公司	一种多聚(adp-核糖)聚合酶抑制剂
CN103325380B (zh)	2012-03-23	2017-09-12	杜比实验室特许公司	用于信号增强的增益后处理
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
US10874641B2 (en)	2016-07-28	2020-12-29	Mitobridge, Inc.	Methods of treating acute kidney injury
AU2017355402A1 (en)	2016-11-02	2019-05-30	Health Research, Inc.	Combination treatment with antibody-drug conjugates and PARP inhibitors
US20240343727A1 (en) *	2021-08-17	2024-10-17	InventisBio Co., Ltd.	Pyridazinone or pyridinone compounds, preparation methods and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58116471A (ja) *	1981-12-29	1983-07-11	Nippon Kayaku Co Ltd	４−ヒドロキシメチル−１−フタラゾンエステル誘導体およびその塩
US4939140A (en) *	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
WO1996005176A1 (fr)	1994-08-09	1996-02-22	Eisai Co., Ltd.	Compose de pyridazine condense
US6635642B1 (en)	1997-09-03	2003-10-21	Guilford Pharmaceuticals Inc.	PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU6966498A (en)	1997-12-02	1998-10-30	Dr. Reddy's Research Foundation	Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
CO5070700A1 (es)	1998-06-05	2001-08-28	Basf Ag	Genes novedosos de (adp-ribosa) polimerasa
ITMI981671A1 (it)	1998-07-21	2000-01-21	Zambon Spa	Derivati ftalazinici inibitori della fosfodisterasi 4
ITMI981670A1 (it)	1998-07-21	2000-01-21	Zambon Spa	Derivati ftalazinici inibitori della fosfodiesterasi 4

1999
- 1999-05-11 DE DE19921567A patent/DE19921567A1/de not_active Withdrawn
2000
- 2000-05-03 ES ES00934980T patent/ES2284499T3/es not_active Expired - Lifetime
- 2000-05-03 TR TR2001/03236T patent/TR200103236T2/xx unknown
- 2000-05-03 EP EP00934980A patent/EP1231982B1/fr not_active Expired - Lifetime
- 2000-05-03 CA CA002372704A patent/CA2372704A1/fr not_active Abandoned
- 2000-05-03 BR BR0010428-0A patent/BR0010428A/pt not_active IP Right Cessation
- 2000-05-03 SK SK1595-2001A patent/SK286676B6/sk not_active IP Right Cessation
- 2000-05-03 JP JP2000616761A patent/JP2003502286A/ja active Pending
- 2000-05-03 PL PL00352150A patent/PL352150A1/xx not_active Application Discontinuation
- 2000-05-03 CZ CZ20014038A patent/CZ20014038A3/cs unknown
- 2000-05-03 AU AU50640/00A patent/AU5064000A/en not_active Abandoned
- 2000-05-03 IL IL14614800A patent/IL146148A0/xx unknown
- 2000-05-03 KR KR1020017014342A patent/KR20020000642A/ko not_active Ceased
- 2000-05-03 CN CN00808074A patent/CN1399573A/zh active Pending
- 2000-05-03 HU HU0202477A patent/HUP0202477A3/hu unknown
- 2000-05-03 US US09/959,404 patent/US6903098B1/en not_active Expired - Fee Related
- 2000-05-03 DE DE50014190T patent/DE50014190D1/de not_active Expired - Lifetime
- 2000-05-03 AT AT00934980T patent/ATE357272T1/de not_active IP Right Cessation
- 2000-05-03 WO PCT/EP2000/003967 patent/WO2000067734A2/fr not_active Ceased
2001
- 2001-10-26 BG BG106056A patent/BG106056A/xx unknown
- 2001-11-08 NO NO20015462A patent/NO20015462D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ20014038A3 (cs)	2002-06-12
EP1231982A2 (fr)	2002-08-21
NO20015462L (no)	2001-11-08
BR0010428A (pt)	2002-04-30
DE50014190D1 (de)	2007-05-03
ES2284499T3 (es)	2007-11-16
SK15952001A3 (sk)	2002-08-06
ATE357272T1 (de)	2007-04-15
PL352150A1 (en)	2003-07-28
EP1231982B1 (fr)	2007-03-21
KR20020000642A (ko)	2002-01-05
WO2000067734A3 (fr)	2002-06-20
AU5064000A (en)	2000-11-21
NO20015462D0 (no)	2001-11-08
CA2372704A1 (fr)	2000-11-16
DE19921567A1 (de)	2000-11-16
HUP0202477A3 (en)	2003-02-28
TR200103236T2 (tr)	2004-08-23
BG106056A (en)	2002-06-28
SK286676B6 (sk)	2009-03-05
HUP0202477A2 (hu)	2002-12-28
WO2000067734A2 (fr)	2000-11-16
CN1399573A (zh)	2003-02-26
JP2003502286A (ja)	2003-01-21
US6903098B1 (en)	2005-06-07

Publication	Publication Date	Title
IL146148A0 (en)	2002-07-25	Use of phthalazine derivatives
MY135732A (en)	2008-06-30	5,6-trimethylenepyrimidin - 4 - one compounds
MY122771A (en)	2006-05-31	Heterocyclically substituted benzimidazoles, their preparation and use thereof
ZA991975B (en)	1999-09-27	Enzyme inhibitors.
AU2352201A (en)	2001-07-16	Improved lysosomal enzymes and lysosomal enzyme activators
DK1117771T3 (da)	2003-06-16	Tørstofformige phytasesammensætninger
EP1818396A3 (fr)	2007-12-19	Variantes d'Alpha Amylasa
EP1144373A3 (fr)	2002-01-02	Inhibiteurs de la serine protease
ZA200006577B (en)	2002-04-24	Phthalazine derivatives as phosphodiesterase 4 inhibitors.
TR200101400T2 (tr)	2001-11-21	2-Fenilbenzimidazoller ve 2-fenilindoller, hazırlanmaları ve kullanımları
MY136037A (en)	2008-08-29	Biphenyl pyrimidone lp-pla2 inhibitors
WO1996021730A3 (fr)	1996-10-10	Ribozymes comportant un site de liaison de proteine arn
ZA200108015B (en)	2003-03-26	Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases.
WO2001070204A3 (fr)	2002-08-01	Inhibiteurs a selectivite elevee de l'activateur de type urokinase du plasminogene
ZA978307B (en)	1998-03-19	3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase.
WO2001005821A3 (fr)	2001-07-19	Utilisations de l'il-10 virale
AU7126900A (en)	2001-04-10	Enzyme inhibitors
PL353214A1 (en)	2003-11-03	Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
GB9924522D0 (en)	1999-12-15	Enzyme inhibitors
GB9816358D0 (en)	1998-09-23	Enzyme inhibitors
AU2002221966A1 (en)	2002-06-11	Enzyme with proteolytic activity
WO2001060986A3 (fr)	2002-02-28	Enzymes hydrolases a activite selective
AU6846300A (en)	2001-03-13	Use of cyamemazine for cold turkey benzodiazepine treatment
BG105252A (en)	2001-12-29	Isoquinolines as urokinase inhibitors
WO2002020091A3 (fr)	2002-11-21	Compositions antithrombotiques